GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

GETI.B

187.6

+1.85%↑

VITR

140.7

+1.44%↑

EKTA.B

48.62

+0.54%↑

BIOAB

180

+2.04%↑

RAY.B

325

0%↓

Search

Camurus AB

Suletud

604 2.11

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

585

Max

606.5

Põhinäitajad

By Trading Economics

Sissetulek

31M

197M

Müük

5.2M

558M

P/E

Sektori keskmine

64.511

50.291

Aktsiakasum

3.29

Kasumimarginaal

35.328

Töötajad

265

EBITDA

21M

190M

Turustatistika

By TradingEconomics

Turukapital

3.2B

35B

Eelmine avamishind

601.89

Eelmine sulgemishind

604

Camurus AB Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. juuni 2025, 20:51 UTC

Tulu

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. juuni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. juuni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. juuni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. juuni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. juuni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. juuni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. juuni 2025, 18:39 UTC

Market Talk
Tulu

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. juuni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. juuni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. juuni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. juuni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. juuni 2025, 17:08 UTC

Tulu

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. juuni 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. juuni 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. juuni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. juuni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Camurus AB Prognoos

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.